GLP-1 Insurance Coverage Shrinks; Zepbound and Wegovy Lose Coverage for 12M Each

According to NPR reporting on April 22, based on GoodRx analysis, between 2025 and 2026, Zepbound lost coverage for 12 million patients and Wegovy for 12 million. The remaining 88% covered face restrictions including prior authorization or BMI requirements of 40 or higher. CVS Caremark excluded Zepbound from its formulary starting in July. Patients are shifting to compounded medications with out-of-pocket costs reaching $300 per month.